SanBio Co., Ltd.
Tokyo, JapanSee on the mapFounded 2001
- Series D
- Stroke
SanBio is a biotechnology company developing regenerative cell medicines for central nervous system disorders, including traumatic brain injury and stroke. Its lead cell therapy, AKUUGO®, has received conditional, time-limited approval in Japan, and the company is preparing for its commercial launch while pursuing broader indications and global development.
- RaisedTotal raised
- $570M
- Jan 2026Latest priced round, Jan 2026
- Series D
- Investors
- 6
- Founded
- 2001
- Employees
- 11–50
reccy insights
SanBio’s central focus is regenerative cell medicine for neurological conditions, including stroke and traumatic brain injury. The company is preparing for commercial launch while continuing broader indication and global development work. An undated growth signal identifies Dr. Shilpa Sambashivan as appointed CEO and board member, but gives no appointment date. Financing entries include a $287 million Series D dated January 2026, with RTW Investments, Hengdian Group, SR One, TCG Crossover, RA Capital Management, HBM Healthcare Investments, Invus, SilverArc Capital, and Adage Capital Management listed as lead investors. Earlier listed financing includes a $162 million Series D in January 2024.
Written by reccy's AI from company sites, press and funding records · updated Nov 2026
What makes SanBio Co., Ltd. distinct
- 01Focuses on regenerative cell medicines for neurological conditions with limited effective treatment options.
- 02AKUUGO® has received conditional, time-limited approval in Japan for a brain-related indication.
- 03Develops therapies intended to promote regenerative processes and restore lost motor or sensory function.
- 04Combines Japanese operations with a U.S. subsidiary and aims to advance regenerative medicine globally.
Technology & products4
- AKUUGO® Suspension for Intracranial Implantation
Regenerative cell medicine for a brain-related indication; it has received conditional, time-limited approval in Japan.
- SB623
Regenerative cell therapy in clinical development for chronic motor impairments following stroke and traumatic brain injury.
- SB618
Enhanced type-mesenchymal stem cells in development for peripheral neuropathy.
+ 1 more: SB308
Recent updates3
- Oct 7, 2026Product launch
Notice Regarding the First Post-Marketing Administration of AKUUGO® Suspension for Intracranial Implantation
sanbio.com - Dec 8, 2025Team change
Appointment of Two Corporate Officers in the Quality Compliance & Regulatory Affairs Division and the Production Division
sanbio.com - May 30, 2025Team change
Keita Mori, Representative Director and President of SanBio, Appointed Chairman of Samurai Biotech Association
sanbio.com
Funding
- Series DJan 2026$287MLed by RTW Investments, Hengdian Group, SR One, TCG Crossover, RA Capital Management, HBM Healthcare Investments, Invus, SilverArc Capital, Adage Capital Management
- Series DJan 2024$162MLed by Leaps by Bayer, RTW Investments, Apeloa Pharmaceutical
- Post-IPO EquityJan 2020Mizuho Bank
Investors19
- Mizuho Bank
- 三菱UFJ信託銀行(株)
- The Column Group
- Samsara Bio Capital
- Leaps by Bayer
- Apeloa Pharmaceutical
- Hengdian Group
- SR One
- HBM Healthcare Investments
- Nissay Capital
About SanBio Co., Ltd.
- Products
- AKUUGO® Suspension for Intracranial Implantation, SB623, SB618, SB308
- Leadership
- Dr. Shilpa Sambashivan, CEO and board member
- Focus areas
- Regenerative medicine, cell therapy, neurology, central nervous system, tbi, stroke, biotechnology, clinical development
- Headquarters
- Tokyo, Japan
- Founded
- 2001
- Employees
- 11–50
- Status
- Active · public company